RBR-29gj42尚未招募1 期
Control of Type 2 Diabetes Mellitus: Analysis of an Intervention Program with Information about the Disease Via Phone Calls
niversidade Federal do Ceará - Departamento de Enfermagem0 个研究点开始时间: 2013年7月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •Having type 2 diabetes for at least one year;Having more than 18 years old;Owning telephone contact;Being able to come to the unit for blood collection;Being able to self-monitoring of blood glucose and self-administration of medicines;Being able to understand the goals, methods and treatment procedures.
排除标准
- •Owning hemoglonina glycated less than 7%;Have complications from the disease: kidney failure, blindness and amputation of limbs;Submit severe cardiovascular disease, high blood pressure or mental illness;Be participating in research with similar goals, made by other researchers.
研究者
相似试验
已完成
3 期
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusType 2 DiabetesNCT01451398Mannkind Corporation353
已完成
3 期
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00351585Novartis39
进行中（未招募）
1 期
Automated blood glucose control with insulin and glucagon in patients with type 1 diabetesPatients with type 1 diabetesMedDRA version: 20.0Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 100000004861EUCTR2019-001631-31-DKSteno Diabetes Center Copenhagen13
进行中（未招募）
不适用
A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF 1g, 2g, AND 4 g V0251 EFFICACY AND TOLERANCE IN VESTIBULAR NEURITIS - NDV0251 is a new investigational agent which is being developped for the treatment of symptomatic vertiginous crisis.MedDRA version: 9.1Level: LLTClassification code 10047339Term: Vertiginous syndromes and other disorders of vestibular systemEUCTR2007-005054-23-ITPIERRE FABRE MEDICAMENT120
终止
2 期
A clinical, double-blind, randomized study to assess the effects and safety of Ivermectin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicSevere acute respiratory syndrome SARSA00-B99RBR-7hzhwdHospital de Base de São José do Rio Preto